Methods for predicting anti-cancer response
AssigneesDana-Farber Cancer Institute, Inc., Technical University of Denmark, Children's Medical Center Corporation, The Brigham and Women's Hospital, Inc.
InventorsAndrea L. Richardson, Zhingang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
Life of this patent
Estimating the term…
Abstract
The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
Claims32
A method for predicting the outcome of anti-cancer treatment of a human subject with a cell hyperproliferative disorder, comprising determining a global chromosomal aberration score (GCAS), comprising obtaining a biological sample from the human subject and 5 determining whether a plurality of chromosomal regions displaying a chromosomal aberration exists within a plurality of chromosomal loci, wherein said chromosomal aberrations are selected from the group consisting of allelic imbalance (NAT), loss of heterozygosity (NLon), copy number aberrations (NcNA), copy number gain (NcNG), copy number decrease (NcT,TD) and combinations thereof, relative to a control, and wherein the 10 presence of a plurality of chromosomal regions displaying said chromosomal aberrations predicts the outcome of anti-cancer treatment of the human subject.
(canceled)
Dependencies are inferred from the claim text.